WuXi Biologics Unveils WuXia™ RidGS for Cell Line Advancements
WuXi Biologics, known for its substantial contributions to the biopharmaceutical sector, has recently introduced an innovative platform titled WuXia™ RidGS. This cutting-edge solution is tailored for the development of cell lines that do not rely on antibiotics. What sets this platform apart is its high-yield glutamine synthetase (GS)-knockout system, anchored in the widely recognized Chinese hamster ovary (CHO) expression system.
Understanding the WuXia™ RidGS Platform
WuXia™ RidGS utilizes advanced zinc finger nucleases (ZFN) technology to execute precise knockouts of the endogenous GS gene within CHO cells. By leveraging this technology, the platform ensures robust cell growth and exceptional productivity, key qualities for the biopharmaceutical manufacturing process. Notably, the platform boasts an average clonal expression level of over 6 g/L for monoclonal antibodies (mAbs), making it highly effective for various therapeutic applications.
High Quality and Consistent Production
One of the most significant advantages of the WuXia™ RidGS platform is its ability to maintain stability and uniformity in production. Without the necessity for antibiotics, this platform provides clients with a continuous and sustainable production line, evident from long-term cell line stability studies. Such reliable output ensures that the therapeutic proteins developed maintain high purity and favorable glycosylation patterns, which are essential for optimal efficacy in medical applications.
WuXi Biologics' Commitment to Innovation
Dr. Chris Chen, the CEO of WuXi Biologics, expressed enthusiasm regarding the launch, highlighting how WuXia™ RidGS represents a significant enhancement in the company's technology offerings. His commitment resonates through the emphasis placed on catering to the nuanced demands of global biopharmaceutical clients. By providing innovative platforms like WuXia™ RidGS, WuXi Biologics actively shapes the landscape of therapeutic protein development, ensuring faster delivery of life-saving medicines to patients around the world.
About WuXia™ Cell Line Development
The WuXia™ platform family is well-regarded for its exemplary performance in biomanufacturing. With capabilities of generating cell line yields as high as 11 g/L, it has gained acceptance from regulatory bodies globally. WuXia™ has successfully created over 900 cell lines for monoclonal and bispecific antibodies, naming conventions that reflect the advanced methodologies employed in its development. The introduction of WuXia™ RidGS aligns perfectly with the existing platforms, catering to the evolving needs of WuXi Biologics' diverse clientele.
About WuXi Biologics
WuXi Biologics operates as a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), with a focus on providing end-to-end solutions across the biologics spectrum. The company's services enable partners to navigate through the complexities of product development, from initial concepts to full commercialization. Timothy achieves this by leveraging a workforce of over 12,000 skilled professionals distributed across multiple key locations. This global presence empowers WuXi Biologics to maintain high standards of efficiency and cost-effectiveness in biologics development.
Commitment to Sustainability
Recognizing the importance of environmental, social, and governance (ESG) initiatives, WuXi Biologics integrates these principles into its core strategy. The company not only utilizes cutting-edge biomanufacturing processes but also seeks to incorporate clean energy solutions within its operational facilities. An ESG committee, headed by the CEO, actively drives the company's commitment to sustainability, ensuring that business operations align with broader societal goals.
Frequently Asked Questions
What is WuXia™ RidGS?
WuXia™ RidGS is a high-yield glutamine synthetase knockout cell line platform developed by WuXi Biologics, focused on non-antibiotic cell line development.
What are the benefits of using WuXia™ RidGS?
The platform ensures high clonal expression levels, cell line stability, and exceptional product quality without the need for antibiotics.
Who leads WuXi Biologics?
Dr. Chris Chen serves as the CEO of WuXi Biologics, overseeing its strategic direction and innovation efforts.
How does WuXi Biologics contribute to sustainability?
WuXi Biologics prioritizes ESG principles in its operations by utilizing clean energy solutions and implementing next-generation biomanufacturing technologies.
What is the significance of the WuXia™ platform family?
The WuXia™ platform family is recognized for its high performance in generating cell lines for therapeutic proteins, aligning with regulatory standards worldwide.
